Immix Biopharma, Inc. (IMMX)
Market Cap | 59.17M |
Revenue (ttm) | n/a |
Net Income (ttm) | -18.21M |
Shares Out | 26.41M |
EPS (ttm) | -0.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 125,042 |
Open | 2.160 |
Previous Close | 2.150 |
Day's Range | 2.151 - 2.300 |
52-Week Range | 1.550 - 7.750 |
Beta | 0.17 |
Analysts | Strong Buy |
Price Target | 10.50 (+368.75%) |
Earnings Date | Aug 9, 2024 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislel... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMMX stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 368.75% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/d/press15-2547402.jpg)
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
![](https://cdn.snapi.dev/images/v1/i/x/press13-2547399.jpg)
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis
![](https://cdn.snapi.dev/images/v1/p/c/press2-2512879.jpg)
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapie...
![](https://cdn.snapi.dev/images/v1/i/e/conf18-2482094.jpg)
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmu...
![](https://cdn.snapi.dev/images/v1/d/b/press2-2424089.jpg)
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201...
![](https://cdn.snapi.dev/images/v1/o/u/press19-2397203.jpg)
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for: EU proto...
![](https://cdn.snapi.dev/images/v1/b/k/press12-2378315.jpg)
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-20...
![](https://cdn.snapi.dev/images/v1/6/y/press4-2371562.jpg)
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell thera...
![](https://cdn.snapi.dev/images/v1/5/y/press15-2333194.jpg)
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell t...
![](https://cdn.snapi.dev/images/v1/8/o/press16-2308649.jpg)
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United St...
![](https://cdn.snapi.dev/images/v1/n/q/press18-2286032.jpg)
Immix Biopharma 12 Month Review Progress Update
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 1...
![](https://cdn.snapi.dev/images/v1/u/3/press16-2268366.jpg)
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies f...
![](https://cdn.snapi.dev/images/v1/v/u/press9-2264628.jpg)
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU protoc...
![](https://cdn.snapi.dev/images/v1/2/p/press8-2261223.jpg)
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies f...
![](https://cdn.snapi.dev/images/v1/f/a/press11-2260724.jpg)
Immix Biopharma Announces Proposed Public Offering of Common Stock
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today...
![](https://cdn.snapi.dev/images/v1/j/u/press1-2242253.jpg)
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapi...
![](https://cdn.snapi.dev/images/v1/a/f/press5-2200231.jpg)
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in aut...
![](https://cdn.snapi.dev/images/v1/k/s/press20-2191203.jpg)
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior ...
![](https://cdn.snapi.dev/images/v1/l/5/conf8-2177999.jpg)
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies f...
![](https://cdn.snapi.dev/images/v1/b/y/press10-2168845.jpg)
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies fo...
![](https://cdn.snapi.dev/images/v1/t/7/press7-2167264.jpg)
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
LOS ANGELES, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies fo...
![](https://cdn.snapi.dev/images/v1/h/6/press20-2141574.jpg)
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy Updated results will be communicated at the presentation time December 10, 2023 ...
![](https://cdn.snapi.dev/images/v1/i/u/press6-2141461.jpg)
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy 98% overall response rate observed in relapsed/refractory multiple...
![](https://cdn.snapi.dev/images/v1/k/3/press18-2122698.jpg)
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella...
![](https://cdn.snapi.dev/images/v1/k/p/press11-2104609.jpg)
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chime...